IRON
Disc Medicine Inc

297
Loading...
Loading...
News
all
press releases
Raymond James bullish on biotech firms on favorable valuation
Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”
investing.com·4mo ago
News Placeholder
More News
News Placeholder
Disc Medicine (NASDAQ:IRON) Given "Outperform" Rating at Wedbush
Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON - Free Report) in a report issued on Monday morning, RTT News reports. Wedbush currently has a $43.00 price...
Ticker Report·1y ago
News Placeholder
FY2024 Earnings Estimate for Disc Medicine, Inc. Issued By Wedbush (NASDAQ:IRON)
Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Wedbush boosted their FY2024 earnings per share (EPS) estimates for Disc Medicine in a report released on Monday, April 1st. Wedbush analyst D...
Ticker Report·1y ago
News Placeholder
Leerink Partnrs Comments on Disc Medicine, Inc.'s Q2 2024 Earnings (NASDAQ:IRON)
Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings per share estimates for shares of Disc Medicine in a report issued on Monday, April...
Ticker Report·1y ago
News Placeholder
Raymond James Reiterates "Outperform" Rating for Disc Medicine (NASDAQ:IRON)
Disc Medicine (NASDAQ:IRON - Get Free Report)s stock had its "outperform" rating reaffirmed by analysts at Raymond James in a report issued on Monday, Marketbeat Ratings reports. They...
Zolmax·1y ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Assembly Biosciences (ASMB Research Report), Nater...
TipRanks Financial Blog·1y ago
News Placeholder
Disc Medicine (NASDAQ:IRON) Shares Down 7.5% Following Analyst Downgrade
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report)'s stock price traded down 7.5% during trading on Tuesday after Stifel Nicolaus lowered their price target on the stock from $104.00 to $71.00...
Ticker Report·1y ago
News Placeholder
Disc Medicine price target lowered by $30 at BMO Capital, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Disc Medicine price target lowered by $33 at Stifel, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Disc Medicine (IRON, $34.31) RSI Indicator left the oversold zone on April 01, 2024
This is a signal that IRON's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
Tickeron - Stocks·1y ago

Latest IRON News

View

Advertisement|Remove ads.

Advertisement|Remove ads.